Orion Portfolio Solutions, LLC Biomarin Pharmaceutical Inc Transaction History

Orion Portfolio Solutions, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$74.43 - $92.22 $486,325 - $602,565	-6,534 Reduced 33.31%	13,083 $1.08 Million
Q1 2024 May 09, 2024	SELL	$83.81 - $99.0 $47,604 - $56,232	-568 Reduced 2.81%	19,617 $1.71 Million
Q4 2023 Feb 09, 2024	SELL	$76.22 - $98.51 $163,873 - $211,796	-2,150 Reduced 9.63%	20,185 $1.95 Million
Q3 2023 Nov 01, 2023	BUY	$85.07 - $94.48 $321,989 - $357,606	3,785 Added 20.4%	22,335 $1.98 Million
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $89,193 - $103,208	-1,029 Reduced 5.26%	18,550 $1.61 Million
Q1 2023 Aug 30, 2023	BUY	$87.74 - $117.27 $90,284 - $120,670	1,029 Added 5.55%	19,579 $1.9 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $1.72 Million - $2.3 Million	19,579 New	19,579 $1.9 Million
Q3 2020 Nov 13, 2020	SELL	$71.87 - $131.03 $16,242 - $29,612	-226 Closed	0 $0
Q2 2020 Aug 19, 2020	SELL	$79.55 - $124.22 $8,273 - $12,918	-104 Reduced 31.52%	226 $28,000
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $1,356 - $1,840	19 Added 6.11%	330 $28,000
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $19,987 - $26,861	311 New	311 $26,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Orion Portfolio Solutions, LLC, based on Form 13F filings with the SEC.

Stay updated on Orion Portfolio Solutions, LLC with notifications on news.